CITIC CLSA cuts target for Alibaba Health stock to HKD 3.70

Published on 10/07/2026 at 02:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal 2026 revenue rose 11.95 percent to HKD 34.26 billion. Alibaba Health stock stood at a HKD 45.8 billion market value on October 6, 2026.

Alibaba Health, BMG0171K1018, Illustration mit AI erstellt.

Alibaba Health Information Technology Limited (BMG0171K1018) faces a lower fiscal 2027 valuation target after CITIC CLSA cut its target to HKD 3.70 on October 3, 2026, citing weaker nutrition-product prospects, as Longbridge reported. Alibaba Health stock was quoted at HKD 2.83 on October 6, 2026, equal to 64.22 percent below its HKD 7.91 52-week high.

Target cut highlights product pressure

The CITIC CLSA update kept an outperform rating but lowered its fiscal 2027 and fiscal 2028 net income expectations. The stated pressure came from weaker nutrition-product sales under regulatory and subsidy changes, giving the target cut a specific operating explanation rather than a purely valuation-based rationale.

The revised HKD 3.70 target stands 30.74 percent above the HKD 2.83 Hong Kong quote. That comparison leaves the market price closer to the HKD 2.75 52-week low than to the annual high, a chart position that makes execution on the core pharmacy and healthcare platforms especially important.

Fiscal 2026 delivered stronger earnings

Alibaba Health reported HKD 34.26 billion of revenue for fiscal 2026 ended March 31, 2026, up 11.95 percent from HKD 30.60 billion in fiscal 2025, according to Reuters. Net income rose 35.17 percent to HKD 1.94 billion from HKD 1.43 billion over the same periods, while operating cash flow reached HKD 1.24 billion in fiscal 2026.

The company identifies its latest annual results announcement as May 15, 2026, on its Alibaba Health investor-relations page. The figures show earnings growth continuing even as the analyst update points to a more selective outlook for nutrition products.

Leadership now combines two top roles

Yu Yong became executive director, chairman and chief executive officer effective September 11, 2026, while Shen Difan left the chairman and CEO roles but remained an executive director, according to MarketScreener. Yu previously led Alibaba Group's 1688.com business from February 2022 to September 2026.

The board said the combined chairman and CEO structure differs from the governance code's separation recommendation. For investors, the leadership change and the target reduction point in opposite directions: strategic control is being consolidated while analysts are applying more caution to near-term product growth.

Stock remains below its annual high

Alibaba Health's Hong Kong quote was HKD 2.83 at 4:08 p.m. HKT on October 6, 2026, with a 52-week range of HKD 2.75 to HKD 7.91 and market capitalization of HKD 45.8 billion. Lang & Schwarz showed a prior close of EUR 0.33 for October 5, 2026.

The further course of trading is shown by the continuously updated real-time quote of Alibaba Health stock.